Thursday 12 June 2025

Pharma & Biotech Start-up & Scale-up News

Featured

Insmed
USA-based Insmed is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Pharmaceutical
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk
28 March 2025
Pharmaceutical
Lexicon pivots back to pipeline after FDA rejection
25 November 2024

Latest Ones To Watch News

Biotechnology
BioNTech to buy CureVac in mRNA mega-merger
12 June 2025
Biotechnology
Stronger antibody responses from Vaxart’s second gen vaccine tech
12 June 2025
Biotechnology
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC
12 June 2025
More ones to watch news >
Reset all filters
Refine Search
Tubulis
Tubulis
Neurocrine Biosciences
Axsome Therapeutics
Cidara Therapeutics
Halda Therapeutics
Opthea
OncoZenge
Soleno Therapeutics
GAIA
Alligator Bioscience
Pliant Therapeutics
Nuvation Bio
Enanta Pharmaceuticals
Basilea
Exsilio Therapeutics
Aphaia Pharma
Avextra
Aurion Biotech
āshibio
UTILITY Therapeutics


Today's issue

The Pharma Letter Podcast — Episode 34 — Is this a revolution in Alzheimer's?
Pharmaceutical
The Pharma Letter Podcast — Episode 34 — Is this a revolution in Alzheimer's?
12 June 2025
Biotechnology
BioNTech to buy CureVac in mRNA mega-merger
12 June 2025
Generics
Russia’s Axelpharm launches generic of AstraZeneca’s Tagrisso
12 June 2025
Biotechnology
BeOne Medicines showcases breakthrough data at EHA
12 June 2025
Pharmaceutical
IQVIA and NVIDIA bring AI age into view
12 June 2025
Pharmaceutical
Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj
12 June 2025
Biotechnology
Kite’s Yescarta shows real-world benefit in LBCL
12 June 2025

Company Spotlight

USA-based Insmed is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.




Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze